A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Heather A Wakelee; Gary Middleton; David Dunlop; Rodryg Ramlau; Natasha Leighl; Desiree Hao; Arturo Lopez-Anaya; Petr Zatloukal; Charlotte D Jacobs

doi:10.1007/s00280-011-1771-0

A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Heather A Wakelee, Gary Middleton, David Dunlop, Rodryg Ramlau, Natasha Leighl, Desiree Hao, Arturo Lopez-Anaya, Petr Zatloukal, Charlotte D Jacobs

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin(®)) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination.

Original language	English
Pages (from-to)	815-24
Number of pages	10
Journal	Cancer Chemotherapy and Pharmacology
Volume	69
Issue number	3
DOIs	https://doi.org/10.1007/s00280-011-1771-0
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-011-1771-0

Cite this

@article{f7fe8c6ce3b448dead257bada084bdec,

title = "A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)",

abstract = "This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin({\textregistered})) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination.",

author = "Wakelee, {Heather A} and Gary Middleton and David Dunlop and Rodryg Ramlau and Natasha Leighl and Desiree Hao and Arturo Lopez-Anaya and Petr Zatloukal and Jacobs, {Charlotte D}",

year = "2012",

doi = "10.1007/s00280-011-1771-0",

language = "English",

volume = "69",

pages = "815--24",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "1432-0843",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

AU - Wakelee, Heather A

AU - Middleton, Gary

AU - Dunlop, David

AU - Ramlau, Rodryg

AU - Leighl, Natasha

AU - Hao, Desiree

AU - Lopez-Anaya, Arturo

AU - Zatloukal, Petr

AU - Jacobs, Charlotte D

PY - 2012

Y1 - 2012

N2 - This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin(®)) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination.

AB - This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin(®)) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination.

U2 - 10.1007/s00280-011-1771-0

DO - 10.1007/s00280-011-1771-0

M3 - Article

C2 - 22057854

SN - 1432-0843

VL - 69

SP - 815

EP - 824

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 3

ER -

A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this